More articles from From The Editor
- Our friend and art director Bob Demarest leaves the CCJM
It is with sadness, modified by appreciation, that I report that a long-time friend of the Journal has decided to part company with us and pursue other opportunities.
- The promise of molecular biology: Efficacy, safety, wallet depletion
Molecular biology is entering its second wave, with effective but expensive treatments. Recombinant human parathyroid hormone (PTH) is a case in point.
- ‘Obvious’ answers aren’t always so simple
In atrial fibrillation, rhythm control seemed “obviously” better than rate control-until randomized trials were done.
- From emerging viruses to cardiovascular disease: Preventive measures matter
Simple things can head off trouble later.
- Antibiotic prophylaxis: Is prevention always worth the cost and risk?
When hard data are lacking we err on the side of caution and consensus.
- Cyber-CME and the Journal’s computer-literate readers
Congratulations to you, our readers, on your adaptability and computer literacy.
- Who is conducting the deadly quartet?
The metabolic syndrome warrants aggressive intervention and prevention, even if we cannot explain it yet.